Linked Life Data

15601620

Source:http://linkedlifedata.com/resource/pubmed/id/15601620

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2004-12-16
pubmed:abstractText
The discovery of new signalling pathways is always followed by the development of pharmacological agents as drugs that can be used in the treatment of diseases resulting from a dysfunction of the signalling pathway in question. Apelin signalling plays a role in the central and peripheral regulation of the cardiovascular system, in water and food intake, and possibly in immune function. Up-regulation of ligand and receptor is also associated with pathophysiological states such as cardiac dysfunction and neovascularisation. Finally, the apelin receptor is a coreceptor for the entry of several HIV-1 and SIV strains. In view of these features, the apelin receptor constitutes a very interesting target for the design of new drugs for treating the prime causes of human mortality.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0898-6568
pubmed:author
pubmed:issnType
Print
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
415-26
pubmed:dateRevised
2011-6-15
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Apelin signalling: a promising pathway from cloning to pharmacology.
pubmed:affiliation
Unité INSERM U-589, TSA 50032, C.H.U. Rangueil, Bât. L3, 1 avenue Jean Poulhès, 31059-Toulouse Cedex 9, France.
pubmed:publicationType
Journal Article, Review